BioTime is committed to developing treatments for hard-to-treat and age-related degenerative diseases. Our work in regenerative medicine leads us to a subsidiary strategy that empowers each management team to develop a business that will eventually become an industry leader.

Read more about our subsidiaries and the way they are changing the future of therapeutic development.